Category page
Therapeutics companies in Europe — biotech directory
A therapeutics company designs and develops drugs — small molecules, biologics, gene/cell therapies, mRNA, peptides, antibodies, or combination products — moving them from discovery through clinical development toward marketing authorization. This page lists European therapeutic developers across all modalities — large pharma majors (Roche, Novartis, Bayer, BioNTech, Novo Nordisk), mid-cap specialists (Lundbeck, Idorsia, Basilea, Genmab), and emerging biotech (BioArctic, Hansa, Atrandi). Each profile is hand-reviewed against leadership disclosure, primary-source verification, and a registry note explaining current operating context and pipeline focus.
Where does this category cluster most clearly?
Therapeutics is currently most visible through Germany (8), Denmark (5), Poland (3), and Sweden (2). Top cities: Copenhagen, Denmark (3), Heidelberg, Germany (2), Ballerup, Denmark (1), and Basel, Switzerland (1). Most legible records: Ascendis Pharma, LEO Pharma, Faron Pharmaceuticals, and Bioceltix.
Which standards and public evidence are already visible?
GMP (7), GLP (8), and FDA-Inspected (1). Latest review: 15 March 2026. Review cycle: March 2026.
Why this category matters
This page brings companies and infrastructure records into one practical category view so users can compare markets and cities more quickly.
Related market brief
A plain reading of the 2026 EU biotech regulatory package — pharmaceutical reform, the European Health Data Space, the AI Act, and the upcoming EU Biotech Act — and what biotech, pharma, and CDMO companies should do about it.
Open related briefBy country
Therapeutics by country
Jump into a country-specific page filtered to this category only.
Explore more
Other categories
Full list
Therapeutics records
22 category records currently match the active filter.
Current review cycle
Ascendis Pharma
HellerupDenmarkTherapeutics
Hellerup headquarters for TransCon-based endocrinology and rare-disease programs with public-company governance and expanding commercial operations.
- Lead
- Jan MikkelsenPresident and Chief Executive Officer
- Scale
- Global biopharma development and commercialization
Current review cycle
LEO Pharma
BallerupDenmarkTherapeutics
Ballerup dermatology headquarters coordinating global specialty-pharma operations, regulatory governance, and medical dermatology portfolio execution.
- Lead
- Christophe BourdonChief Executive Officer
- Scale
- Global specialty-pharma operations
Current review cycle
Faron Pharmaceuticals
TurkuFinlandTherapeutics
Turku immunotherapy headquarters advancing macrophage reprogramming and hematology-oncology programs through regulated clinical development.
- Lead
- Juho JalkanenChief Executive Officer
- Scale
- Clinical-stage therapeutic development
Current review cycle
Bioceltix
WroclawPolandTherapeutics
Wroclaw veterinary biologics company developing allogeneic cell therapies and regulated animal-health products.
- Lead
- Łukasz BzdzionPresident of the Management Board
- Scale
- Veterinary biologics platform
Current review cycle
Heidelberg Pharma
HeidelbergGermanyTherapeutics
Ladenburg antibody-drug-conjugate platform focused on amanitin payload technology and oncology pipeline development.
- Lead
- Dr. Dongzhou Jeffery LiuChief Executive Officer
- Scale
- Clinical-stage ADC platform
Current review cycle
RHEACELL
HeidelbergGermanyTherapeutics
Heidelberg regenerative-medicine company focused on stromal-cell therapies and clinical-stage cell-based products.
- Lead
- Dr. Christoph GanssPhysician, Chief Executive Officer and Founder
- Scale
- Clinical-stage regenerative-medicine platform
Current review cycle
Basilea
BaselSwitzerlandTherapeutics
Basel anti-infectives and oncology-development anchor operating a highly specialized therapeutics portfolio with partnered commercial reach.
- Lead
- David VeitchChief Executive Officer
- Scale
- Clinical and partnered specialty development
Current review cycle
Debiopharm
LausanneSwitzerlandTherapeutics
Lausanne oncology and specialty-therapeutics development anchor operating with a clinical-development and partnering model.
- Lead
- Frédéric LévyChief Executive Officer, Debiopharm International
- Scale
- Clinical and partnered development
Current review cycle
Ryvu Therapeutics
KrakowPolandTherapeutics
Clinical-stage oncology drug discovery and development platform in Krakow focused on small-molecule therapies against emerging cancer targets.
- Lead
- Pawel PrzewiezlikowskiChief Executive Officer and President of the Management Board
- Scale
- Clinical-stage drug discovery
Current review cycle
CureVac
TübingenGermanyTherapeutics
Tübingen mRNA-development and translational-manufacturing anchor with a current executive record and a live RNA platform profile.
- Lead
- Alexander ZehnderChief Executive Officer
- Scale
- Clinical and translational development
Current review cycle
Camurus
LundSwedenTherapeutics
Lund therapeutic-development anchor built around long-acting drug-delivery technologies and late-stage specialty-pharma execution.
- Lead
- Fredrik TibergPresident and Chief Executive Officer
- Scale
- Late-stage and commercial specialty pharma
Current review cycle
Affimed NV
LadenburgGermanyTherapeutics
Heidelberg innate-immunity company developing NK-cell engager and bispecific immunotherapy programs from its ROCK platform for hematologic and solid-tumor targets.
- Lead
- Shawn M. LelandChief Executive Officer and Chairman of the Management Board
- Scale
- Drug Development
Current review cycle
Apogenix AG
BerlinGermanyTherapeutics
Heidelberg immunotherapy developer focused on TNFSF pathway biology and clinical-stage oncology programs built from its asunercept platform.
- Lead
- Dr. Thomas HoegerChief Executive Officer
- Scale
- Clinical Research
Current review cycle
Zealand Pharma
CopenhagenDenmarkTherapeutics
Copenhagen-area peptide therapeutics company focused on obesity, metabolic disease, and specialty indications through discovery and late-stage development.
- Lead
- Adam SteensbergPresident and Chief Executive Officer
- Scale
- Global Biopharma
Current review cycle
Genmab A/S
CopenhagenDenmarkTherapeutics
Copenhagen antibody-therapeutics headquarters running Genmab's platform-engineering, translational science, and late-stage oncology execution from its Valby base.
- Lead
- Jan van de WinkelPresident and Chief Executive Officer
- Scale
- Global Biopharma
Current review cycle
Bayer Pharmaceuticals
LeverkusenGermanyTherapeutics
Leverkusen pharmaceutical anchor spanning commercial therapeutics, process development, analytical quality, and global manufacturing coordination.
- Lead
- Bill AndersonChief Executive Officer
- Scale
- Global commercial manufacturing
Current review cycle
Boehringer Ingelheim
Ingelheim am RheinGermanyTherapeutics
German biopharmaceutical and small-molecule production titan spanning R&D, biologics, fill-finish, and global supply operations.
- Lead
- Hubertus von BaumbachChairman of the Board of Managing Directors
- Scale
- Global therapeutic manufacturing
Current review cycle
Nykode Therapeutics
OsloNorwayTherapeutics
Oslo clinical-stage immunotherapy company running its DNA-based platform, oncology programs, and partner-facing operations from the Oslo Science Park headquarters.
- Lead
- Michael EngsigChief Executive Officer
- Scale
- Drug Development
Current review cycle
Sobi
StockholmSwedenTherapeutics
Stockholm rare-disease headquarters and technical-operations node used as a Nordic benchmark surface for executive review.
- Lead
- Guido OelkersChief Executive Officer
- Scale
- Global rare-disease operations
Current review cycle
Celon Pharma S.A.
ŁomiankiPolandTherapeutics
Integrated oncology and neurology R&D platform with in-house development, manufacturing, and commercial drug operations in Poland. The verified March 2026 record positions Celon as a high-conviction therapeutic innovation anchor in the cluster.
- Lead
- Dr. Maciej WieczorekCEO and President of the Management Board
- Scale
- Integrated therapeutic R&D and manufacturing
Current review cycle
BioNTech SE
MainzGermanyTherapeutics
Mainz mRNA and immunotherapy headquarters coordinating BioNTech's oncology pipeline, manufacturing network, and clinical execution ahead of the planned 2026 launch window.
- Lead
- Ugur SahinCEO and Co-Founder
- Scale
- Commercial Phase
Current review cycle
H. Lundbeck A/S
CopenhagenDenmarkTherapeutics
Copenhagen-area neuroscience therapeutics company combining brain-disease R&D, regulated pharmaceutical supply, and global commercial operations.
- Lead
- Charl van ZylPresident and CEO
- Scale
- Global Supply
FAQ
Frequently asked questions
- What does "therapeutics company" mean?
- A company that develops drugs to treat or prevent disease, as distinct from contract manufacturers (CDMOs), service organizations (CROs), or tools/diagnostics suppliers. Therapeutic developers own a pipeline of drug candidates and either develop them in-house, license them out, or commercialize them at scale.
- Which European countries lead in therapeutics?
- Switzerland (Roche, Novartis, Idorsia, Basilea, Noema), Germany (BioNTech, Bayer, Merck KGaA), Denmark (Novo Nordisk, Lundbeck, Genmab, Zealand Pharma), Sweden (AstraZeneca, BioArctic, Sobi), and emerging markets in Poland (Ryvu, Captor), Lithuania (Atrandi, CasZyme), and Estonia (Asper Biogene). The directory covers all of these with hand-reviewed profiles.
- How are therapeutics companies verified in this directory?
- Every profile is hand-reviewed against an audit framework: leadership identity confirmed by primary source, physical site address sourced from official disclosures, regulatory and pipeline context backed by certification documents or filings, and a registry note explaining the company's current operating focus and clinical stage where applicable.
- Can I compare two therapeutic developers side by side?
- Yes — use the Compare button on any company card to add it to a comparison set (up to 3 companies), then open the /compare page for a side-by-side view of leadership, certifications, and operating scale.
Next step
Read the category, then move into cities and countries.
Use city pages for local concentration, country pages for market context, and the methodology page when you want to understand how records are reviewed.